Literature DB >> 14722897

Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1.

Steven G Deeks1, Jeffrey N Martin, Elizabeth Sinclair, Jeff Harris, Torsten B Neilands, Holden T Maecker, Elilta Hagos, Terri Wrin, Christos J Petropoulos, Barry Bredt, Joseph M McCune.   

Abstract

Antiretroviral (ARV)-treated patients often maintain low to moderate levels of viremia, despite the emergence of drug-resistant human immunodeficiency virus (HIV). We studied host and viral factors that may contribute to the control of viral replication in a cohort of 189 adults. Among ARV-treated patients with detectable viremia, there was a bell-shaped relationship between Gag-specific CD4+ T cell responses and viremia, with the highest cellular immune responses observed in patients with plasma HIV RNA levels of 1000-10,000 copies/mL. In contrast, there was a negative association between Gag-specific CD4+ T cell responses and viremia among ARV-untreated individuals with wild-type HIV. Strong cellular immune responses among individuals with drug-resistant HIV predicted subsequent lack of virological progression. Finally, there was a positive correlation between replicative capacity and viremia. Collectively, these data suggest that the selection of drug-resistance mutations may reduce the pathogenic potential of HIV, which leads to a balanced state of enhanced cellular immunity and low-level viremia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722897     DOI: 10.1086/380098

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  37 in total

1.  CMV antigen-specific CD4+ and CD8+ T cell IFNgamma expression and proliferation responses in healthy CMV-seropositive individuals.

Authors:  Elizabeth Sinclair; Douglas Black; C Lorrie Epling; Alexander Carvidi; Steven Z Josefowicz; Barry M Bredt; Mark A Jacobson
Journal:  Viral Immunol       Date:  2004       Impact factor: 2.257

2.  The immune response to AIDS virus infection: good, bad, or both?

Authors:  Steven G Deeks; Bruce D Walker
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

3.  Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers.

Authors:  April L Ferre; Donna Lemongello; Peter W Hunt; Megan M Morris; Juan Carlos Garcia; Richard B Pollard; Hal F Yee; Jeffrey N Martin; Steven G Deeks; Barbara L Shacklett
Journal:  J Virol       Date:  2010-07-28       Impact factor: 5.103

4.  Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.

Authors:  Koen K A Van Rompay; Raman P Singh; Walid Heneine; Jeffrey A Johnson; David C Montefiori; Norbert Bischofberger; Marta L Marthas
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Antiretroviral drug therapy alters the profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response from Gag to Pol.

Authors:  A C Karlsson; J M Chapman; B D Heiken; R Hoh; E G Kallas; J N Martin; F M Hecht; S G Deeks; D F Nixon
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

6.  HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels.

Authors:  Michael R Jordan; Julie Winsett; Aileen Tiro; Vuth Bau; Rony S Berbara; Christopher Rowley; Nobel Bellosillo; Christine Wanke; Eoin P Coakley
Journal:  World J AIDS       Date:  2013-06

7.  Control of M184V HIV-1 mutants by CD8 T-cell responses.

Authors:  Thomas Vollbrecht; Josef Eberle; Julia Roider; Silja Bühler; Renate Stirner; Nadja Henrich; Ulrich Seybold; Johannes R Bogner; Rika Draenert
Journal:  Med Microbiol Immunol       Date:  2011-12-27       Impact factor: 3.402

8.  Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.

Authors:  Steven G Deeks; Becky Schweighardt; Terri Wrin; Justin Galovich; Rebecca Hoh; Elizabeth Sinclair; Peter Hunt; Joseph M McCune; Jeffrey N Martin; Christos J Petropoulos; Frederick M Hecht
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

9.  Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.

Authors:  M Christian Tjiam; James P A Taylor; Mazmah A Morshidi; Lucy Sariputra; Sally Burrows; Jeffrey N Martin; Steven G Deeks; Dino B A Tan; Silvia Lee; Sonia Fernandez; Martyn A French
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

10.  Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease.

Authors:  David M Naeger; Jeffrey N Martin; Elizabeth Sinclair; Peter W Hunt; David R Bangsberg; Frederick Hecht; Priscilla Hsue; Joseph M McCune; Steven G Deeks
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.